Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorFujian Cancer Hospital
About this trial
This is a prospective single-arm exploratory clinical study. The efficacy and safety of camrelizumab combined with chemoradiotherapy and camrelizumab combined with chemotherapy were evaluated in patients with advanced esophageal cancer who had not previously received any systemic antitumor therapy for esophageal cancer.
Eligibility criteria
Qualifiers
Sign written informed consent and voluntarily participate in this study;
Patients with esophageal squamous cell carcinoma confirmed by histopathology and/or immunohistochemistry (8th edition 2017) had UICC/AJCC TNM stage IVA or oligometastatic stage IVB;
Survival is expected to exceed 3 months
Age 18-75;
Disqualifiers
The presence of uncontrollable pleural effusion, pericardial effusion or ascites that require repeated drainage;
Poor nutritional status, BMI < 18.5 Kg/m²; If symptomatic nutritional support was corrected before randomization, enrollment could be considered after evaluation by the principal investigator;
Gastrointestinal bleeding (bleeding volume > 200ml/ day);
Patients with deep ulcers as determined by the investigator;
Trial design
Treatments tested in this trial
- camrelizumab
- Paclitaxel drugs
- Platinum drug
- Radiation
Treatment groups
75 Participants
are divided into 1 treatment groupLocations
1Fujian Cancer Hospital Fuzhou China
Sponsors and collaborators
Fujian Cancer Hospital
Lead sponsor
Source ClinicalTrials.gov